Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ... Retina 33 (10), 2012-2017, 2013 | 133 | 2013 |
Symptomatic vitreomacular adhesion TL Jackson, E Nicod, A Simpson, A Angelis, F Grimaccia, P Kanavos Retina 33 (8), 1503-1511, 2013 | 122 | 2013 |
Differences in costs of and access to pharmaceutical products in the EU P Kanavos, S Vandoros, R Irwin, E Nicod, M Casson EPRS: European Parliamentary Research Service, 2011 | 119 | 2011 |
Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL) L Annemans, S Aymé, Y Le Cam, K Facey, P Gunther, E Nicod, M Reni, ... Orphanet journal of rare diseases 12, 1-15, 2017 | 101 | 2017 |
Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and metaanalysis TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ... Retina 33 (6), 1099-1108, 2013 | 100 | 2013 |
Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions E Nicod, P Kanavos Health Policy 108 (2-3), 167-177, 2012 | 100 | 2012 |
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug … E Nicod The European Journal of Health Economics 18, 715-730, 2017 | 88 | 2017 |
Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature TL Jackson, E Nicod, A Angelis, F Grimaccia, E Pringle, P Kanavos Retina 37 (5), 886-895, 2017 | 85 | 2017 |
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom A Angelis, P Kanavos, J López-Bastida, R Linertová, E Nicod, ... BMC health services research 15, 1-8, 2015 | 73 | 2015 |
HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries E Nicod, L Annemans, A Bucsics, A Lee, S Upadhyaya, K Facey Health Policy 123 (2), 140-151, 2019 | 70 | 2019 |
The impact of health technology assessments: an international comparison P Kanavos, E Nicod, S Van Den Aardweg, S Pomedli EURO OBSERVER-HEALTH POLICY BULLETIN OF THE EUROPEAN OBSERVATORY ON HEALTH …, 2010 | 58 | 2010 |
Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: a mixed methods study E Nicod, P Kanavos Health Policy 120 (1), 35-45, 2016 | 54 | 2016 |
What is wrong with orphan drug policies? Suggestions for ways forward P Kanavos, E Nicod Value in health 15 (8), 1182-1184, 2012 | 52 | 2012 |
Scientific and social value judgments for orphan drugs in health technology assessment E Nicod, P Kanavos International Journal of Technology Assessment in Health Care 32 (4), 218-232, 2016 | 45 | 2016 |
Short-and long-term effects of value-based pricing vs. external price referencing P Kanavos, E Nicod, J Espin, S Van Den Aardweg Eminet, LSE, 2010 | 44 | 2010 |
The use of patient-reported outcome measures in rare diseases and implications for health technology assessment A Whittal, M Meregaglia, E Nicod The Patient-Patient-Centered Outcomes Research 14, 485-503, 2021 | 42 | 2021 |
Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel KM Facey, J Espin, E Kent, A Link, E Nicod, A O’Leary, E Xoxi, ... Pharmacoeconomics 39, 1021-1044, 2021 | 41 | 2021 |
Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches E Nicod, A Whittal, M Drummond, K Facey Orphanet journal of rare diseases 15, 1-14, 2020 | 36 | 2020 |
Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer O Ciani, M Cucciniello, F Petracca, G Apolone, G Merlini, S Novello, ... BMJ open 9 (2), e025483, 2019 | 35 | 2019 |
Dealing with uncertainty and accounting for social value judgments in assessments of orphan drugs: evidence from four European countries E Nicod, KB Brigham, I Durand-Zaleski, P Kanavos Value in Health 20 (7), 919-926, 2017 | 35 | 2017 |